Bavarian Nordic   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kvistgaard Denmark (1994)

Organization Overview

First Clinical Trial
2001
NCT00189943
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Bavarian Nordic | Bavarian Nordic GmbH | Bavarian Nordic, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Encephalitis (Phase 1)

Encephalomyelitis, Equine (Phase 1)

Hemorrhagic Fever, Ebola (Phase 3)

Hemorrhagic Fevers, Viral (Phase 3)

HIV Infections (Phase 2)

Infections (Phase 2)

Lung Neoplasms (Phase 2)

Measles (Phase 2)

Monkeypox (Phase 3)

Neoplasm Metastasis (Phase 1)

Papillomavirus Infections (Phase 2)

Prostatic Neoplasms (Phase 3)

Respiratory Syncytial Virus Infections (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 1)

Smallpox (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Vaccinia (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial APIs: 27